Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis | Zendy

Wirongrong Chierakul | Zendy; Jinda Wangboonskul | Zendy; Thida Singtoroj | Zendy; Wirichada Pongtavornpinyo | Zendy; John M. Short | Zendy; Bina Maharjan | Zendy; Vanaporn Wuthiekanun | Zendy; David A. B. Dance | Zendy; Prapit Teparrukkul | Zendy; Niklas Lindegårdh | Zendy; Sharon J. Peacock | Zendy; N. P. Day | Zendy; Wipada Chaowagul | Zendy; Nicholas J. White | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis

Author(s) -

Wirongrong Chierakul,

Jinda Wangboonskul,

Thida Singtoroj,

Wirichada Pongtavornpinyo,

John M. Short,

Bina Maharjan,

Vanaporn Wuthiekanun,

David A. B. Dance,

Prapit Teparrukkul,

Niklas Lindegårdh,

Sharon J. Peacock,

N. P. Day,

Wipada Chaowagul,

Nicholas J. White

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl389

Subject(s) - amoxicillin , burkholderia pseudomallei , melioidosis , dosing , pharmacokinetics , medicine , antibacterial agent , pharmacodynamics , antibiotics , dose , clavulanic acid , ceftazidime , pharmacology , microbiology and biotechnology , biology , bacteria , genetics , pathology , pseudomonas aeruginosa

We conducted a prospective pharmacokinetic study of oral co-amoxiclav in patients with melioidosis to determine the optimal dosage and dosing interval in this potentially fatal infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research